Biotechnology company Celyad Oncology (Euronext Brussels:CYAD) announced on Thursday that it has sold its C-Cathez transendocardial catheter to CellProthera, including all intellectual property rights and technical documentation.
The catheter will serve as a core component in CellProthera's upcoming Phase 3 clinical trial, enabling targeted stem cell delivery to damaged cardiac tissue.
The agreement provides for up to EUR5m in milestone-based payments and future royalties on net sales. As the consideration is fully deferred, the transaction will not affect Celyad Oncology's current cash runway, which is expected to last through the third quarter of 2026.
CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction.
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
Median Technologies secures FDA clearance for AI lung cancer screening software
Insilico Medicine names new vice president, Clinical Development – Oncology
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001
Hologic receives FDA approval for Aptima HPV assay as primary screening option
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use